近日，临港新片区管委会高新产业和科技创新处发布了《中国（上海）自由贸易试验区临港新片区管理委员会关于公示2024年度第一批高新产业和科技创新专项项目立项的通知》。根据第三方评估机构评审结果，经临港新片区管委会专题会议审议，标新生物申报的关键核心技术研发项目“I类新药GT919用于恶性血液肿瘤治疗的开发”立项通过，将获得管委会的配套资助。
本批专项项目是临港管委会高科处根据《中国（上海）自由贸易试验区临港新片区专项发展资金预算管理办法》（沪财预〔2023〕118号）、《中国（上海）自由贸易试验区临港新片区促进前沿重点产业高质量发展若干政策》（沪自贸临管经〔2023〕193号），为实现前沿产业产业链供应链自主安全可控，支持发展重点产业中填补国内空白、实现国产替代的产品研发，对关键核心技术和颠覆性技术有效突破给予的特别支持。新片区共25个项目获得立项。
此次临港新片区管委会的专项资金支持，对标新生物而言是一股强大的推动力。这不仅显现出临港新片区管委会相关部门对科技创新的深切关注与高度重视，更为标新生物的发展提供了坚实的保障。作为一家专注于蛋白降解技术、处于临床阶段的创新生物医药科技企业，标新生物始终致力于技术的突破和产品的转化，深感使命重大。在此过程中，我们深切明白，创新企业的成长离不开各级政府部门的引导和支持，管委会在科技创新领域的政策扶持，为我们营造了良好的创新环境，提供了宝贵的发展机遇。
下一步，标新生物将以此为契机，充分发挥创新企业优势作用，继续加大创新药研发投入、培养高技术人才队伍、不断注入技术创新的新动能，努力提升企业核心竞争力，以前瞻的眼光、严谨的科学态度，把握生物医药变革发展带来的无限可能，持续推动蛋白降解剂药物研发创新走深走实，为增进民众健康福祉和构建健康中国贡献力量。
Recently, the High-tech Department of the Lin-gang Special Area Administration released the Notice of China (Shanghai) Pilot Free Trade Zone Lin-gang Special Area Administration on the Publication of the First Batch of High-tech Special Projects in the Year of 2024. According to the evaluation results of the third-party evaluator and the consideration of the special meeting of the Lin-gang Special Area Administration, the project of Key Core Technology R&D Project “Development of Class I New Drug GT919 for the Treatment of hematological malignancies” declared by Gluetacs has been approved, and it will be awarded the matching funding by the Administration.This batch of special projects is the special support given by the High-tech Department of the Lin-gang Special Area Administration according to the relevant policies, in order to realize the independency, security and control of the supply chain of the frontier industry chain, to support the development of key industries to fill the gaps in the domestic market, to realize the research and development of domestically produced substitutes, and to give special support to the effective breakthroughs in the key core technologies and transformative technologies. A total of 25 projects in the Special Area won.The special financial support from the Lin-gang Special Area Administrationis a strong driving force for Gluetacs. It not only shows the deep concern and great attention of the relevant departments of Lin-gang Special Area Administration on science and technology innovation, but also provides a solid guarantee for the development of Gluetacs. As an innovative clinical-stage biopharmaceutical technology enterprise specializing in protein degradation technology, Gluetacs has always been committed to technological breakthroughs and scientific research achievement transformation, with deeply aware of the significance of its mission. We deeply understand that the growth of innovative enterprises cannot be separated from the guidance and support of government departments at all levels, and the policy support of the Administration in the field of science and technology innovation has created a favorable innovation environment and provided us with valuable development opportunities.In the next step, Gluetacs will take this opportunity to give full play to the advantages of innovative enterprises, continue to increase investment in R&D of innovative drugs, cultivate a team of high-tech talents, continuously foster new growth drivers of technological innovation, strive to enhance the core capabilities of enterprises, grasp the infinite possibilities brought by the revolution in the field of medicine, and continue to promote the R&D innovation of protein degraders in a deeper and more practical way to contribute to the enhancement of the people's health and well-being and the construction of a healthy China.
标新生物（Gluetacs Therapeutics）是一家专注于研发口服蛋白降解小分子药物的生物医药公司，为上海科技大学孵化的首家生物医药公司，成立于2020年2月，2021年3月正式运营，由多名在蛋白降解领域深耕多年的科学家领衔创立。公司拥有自主知识产权的分子胶降解剂（GLUE）和双机制降解剂（GLUETAC）开发平台，并拥有申请和授权不同国家该领域专利近百项，具备独具特色的差异化技术路线和发展战略。公司现已自主建立人工智能虚拟筛选平台、体外药效筛选平台、药代动力学平台、蛋白质组学平台以及肿瘤动物药效模型平台，实现了完备的全流程药物研发体系建设。标新生物自从2021年3月正式运营以来，成功推动两个候选药物进入临床试验，充分验证和体现了GlueTacs®平台快速发现候选药物和管线推进的能力。标新生物自成立以来受到业内的广泛关注，连续三年获得上海市科技型中小企业称号，荣获2024专精特新中小企业和创新型中小企业称号、2024年度临港新片区科创新锐企业称号、2023上海市高价值专利运营大赛百强、2023中国海归创业大赛三等奖、2023华医榜中国生物医药科技创新价值榜最具成长性小分子创新药企业TOP10、2023临港杯第九届创青春上海青年创新创业大赛一等奖、2022浦东新区全球高校校友科创大赛二等奖，2022中国创新制药企业TOP10、2022第十一届中国创新创业大赛成长组全国赛优秀企业奖、2022第6届医疗健康投资卓悦榜年度生物医药最佳企业、2022第五届中国创翼创业创新大赛上海选拔赛浦东赛区十佳创翼奖、2022浦东新区全球高校校友科创大赛二等奖、2022Venture50新芽榜150强、2021年度全国颠覆性技术创新大赛优秀项目、2021年第二届生物产业年度攀登榜年度最具投资潜质的新锐BioTech、2021中国生物医药产业链创新风云榜金马奖最具关注度新锐企业TOP10奖项。公司陆续获得多项科技部和上海市科委资金支持，纳入临港新片区前沿产业优秀人才安家补贴、重点产业人才补贴、人才引进重点机构名单，知识产权管理体系获得中国专利保护协会认证，多位团队核心成员陆续获得临港新片区十大科技创新先锋人物、谈家桢生命科学产业化奖、杨雄科技创业奖、东方英才创业青年领军人才、上海高层次海外人才和上海市浦江人才等称号。公司也先后成为上海科技大学创新型硕士和工程博士培养单位，并先后与十多位海内外专家教授进行科研研究合作。
About Gluetacs TherapeuticsGluetacs Therapeutics, focusing on the development of oral small molecule protein degrader, is the first biotech company incubated from ShanghaiTech University, Gluetacs was founded in February 2020, and started to operation in March 2021. It was founded by several scientists that have done intensive studies in target protein degradation. The company has independent intellectual property of GLUE degrader and GLUETAC degrader development platform with around 100 patents filed, which has indicated a unique and differentiated technical route and development strategy. The company has established artificial intelligence virtual screening platform, in vitro pharmacodynamics screening platform, pharmacokinetics platform, proteomics platform and in vivo drug pharmacology evaluation platform, and has constructed a complete whole-process drug R&D system. Since its operation in March 2021, Gluetacs Therapeutics has successfully advanced 2 drug candidates into phase I clinical trial, which has demonstrated the GlueTacs® platform's ability to rapidly discover drug candidates and promote pipelines.
